Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

389P - Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial

Date

14 Sep 2024

Session

Poster session 15

Topics

Tumour Site

Breast Cancer

Presenters

Huihui Li

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

H. Li1, D. Zhou2, Z. Yv3, Y. Liao4, J. Huang5, S. sun5, F. Zheng6, B. Li7, S. Fang5, L. Qiang5, G. ren5, X. Wang8, Z. Baoxuan2, B. fan9, X. Zhao10, W. Li10, Z. Wang11, H. Fu12, X. Sun12, Z. Shi13

Author affiliations

  • 1 Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 250117 - Jinan/CN
  • 2 Breast Medical Oncology, Shandong Cancer Hospital and Institute, 250117 - Jinan/CN
  • 3 Breast Medical Oncology, The First School of Clinical Medicine of Binzhou Medical University, 250000 - Binzhou/CN
  • 4 Breast Medical Oncology, The First Affiliated Hospital of Nanchang University, 250000 - Nanchang/CN
  • 5 Breast Medical Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, 250117 - Jinan/CN
  • 6 Breast Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, 100021 - Beijing/CN
  • 7 Breast Cancer Treatment Center, Taian City Central Hospital, Taian/CN
  • 8 Breast Surgery, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN
  • 9 Shandong Cancer Hospital And Institute, Shandong Cancer Hospital and Institute, 250117 - Jinan/CN
  • 10 Oncology Department, Shandong Cancer Hospital Affiliated to Shandong University, 250117 - Jinan/CN
  • 11 The First School Of Clinical Medicine Of Binzhou Medical University, The First School of Clinical Medicine of Binzhou Medical University, Binzhou/CN
  • 12 Shandong Cancer Hospital And Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN
  • 13 Shandong Cancer Hospital And Institute,, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 389P

Background

Antiangiogenic drugs have demonstrated synergistic effect with anti-PD-1 antibody in advanced triple negative breast cancer (TNBC). Anlotinib is an oral multi-target tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Preclinical studies showed that metronomic chemotherapy inhibited angiogenesis and enhanced the efficacy of immunotherapy in TNBC via modulation of the tumor immune microenvironment. We hereby conducted a phase II trial to investigate the efficacy and safety of sintilimab (anti-PD-1 antibody) plus anlotinib and metronomic chemotherapy as a potential novel therapeutic strategy in advanced TNBC and explore potential biomarkers.

Methods

The eligible patients who had received no more than two lines of chemotherapy for metastatic disease were enrolled and received sintilimab (200 mg iv q3w) and anlotinib (12 mg po d1-14 q3w) plus capecitabine (500 mg po, tid) or vinorelbine (40 mg po, tiw) until disease progression or intolerable toxicity. The primary endpoint is objective response rate (ORR) and secondary endpoints are disease control rate (DCR), progression free survival (PFS), and overall survival (OS).

Results

As of April 2024, a total of 43 patients were enrolled, and all patients were evaluable for efficacy. 3 patients (6.97%) achieved complete response (CR). 7 patients (16.27%) achieved partial response (PR). 25 patients (58.14%%) achieved stable disease (SD). The ORR is 23.26% (95%CI 0.12-0.39) and DCR is 81.40% (95%CI 0.67- 0.92). The median PFS was 5.55 months (95%CI 3.33-7.77). The median OS was 24.03 months (95%CI 19.74-28.32). The most common grade 1 or 2 adverse events (AEs) include elevated thyroid stimulating hormone, elevated bilirubin, hand-foot syndrome, leukopenia, nausea. Grade 3 AEs include elevated bilirubin (2.33%, 1/43), hypertension (2.33%, 1/43) and herpes zoster (2.33%, 1/43). No grade 4 or 5 AEs occurred.

Conclusions

Our date showed that sintilimab in combination with anlotinib plus metronomic chemotherapy have shown favorable efficacy and acceptable safety profile in patients with advanced TNBC. Clinical trial information: ChiCTR2100044725.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.